PMID- 34007370
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210520
IS  - 1927-1220 (Electronic)
IS  - 1927-1212 (Print)
IS  - 1927-1212 (Linking)
VI  - 10
IP  - 2
DP  - 2021 Apr
TI  - MYC-Positive Diffuse Large B-Cell Lymphoma in Leukemic Phase at Presentation: A 
      Diagnostic and Therapeutic Challenge.
PG  - 80-82
LID - 10.14740/jh818 [doi]
AB  - Diffuse large B-cell lymphoma (DLBCL) in leukemic phase at presentation is a rare 
      condition, and it can be challenging to differentiate from acute leukemia or 
      other types of non-Hodgkin lymphoma. To obtain an accurate diagnosis 
      immunophenotyping and cytogenetic analyses should be performed. Herein, we report 
      a 54-year-old woman who experienced loss of consciousness and fever. Laboratory 
      test results revealed leukocytosis, anemia, thrombopenia and hypercalcemia. 
      Morphology of blood smear revealed two abnormal cell populations. However a 
      specific diagnosis could not be made. Immunophenotyping showed two different 
      populations, which was consistent with non-Hodgkin lymphoma. A fluorescence in 
      situ hybridization (FISH) showed MYC and BCL2 rearrangements. Finally a leukemic 
      DLBCL was diagnosed and immediately treatment with rituximab cyclophosphamide, 
      doxorubicin, vincristine and prednisone (R-CHOP) was started. Due to 
      MYC-positivity, lenalidomide was added to the therapy regimen. After treatment 
      the patient achieved complete remission without any clinical sequelae, which is 
      still ongoing after 4 years. Lenalidomide is an oral immunomodulatory drug that 
      downregulates MYC gene and is commonly used in patients with multiple myeloma. 
      Moreover, it can also be a promising therapeutic option for patients with 
      MYC-positivity DLBCL presenting in leukemic phase.
CI  - Copyright 2021, Bilgin et al.
FAU - Bilgin, Yavuz Memis
AU  - Bilgin YM
AD  - Department of Internal Medicine, Admiraal de Ruyter Hospital, Goes, the 
      Netherlands.
FAU - Castel, Rob
AU  - Castel R
AD  - Department of Clinical Chemistry, Admiraal de Ruyter Hospital, Goes, the 
      Netherlands.
LA  - eng
PT  - Case Reports
DEP - 20210427
PL  - Canada
TA  - J Hematol
JT  - Journal of hematology
JID - 101635099
PMC - PMC8110231
OTO - NOTNLM
OT  - DLBCL
OT  - Lenalidomide
OT  - Leukemic phase
COIS- The authors declare no conflict of interest.
EDAT- 2021/05/20 06:00
MHDA- 2021/05/20 06:01
PMCR- 2021/04/27
CRDT- 2021/05/19 06:48
PHST- 2021/03/16 00:00 [received]
PHST- 2021/03/30 00:00 [accepted]
PHST- 2021/05/19 06:48 [entrez]
PHST- 2021/05/20 06:00 [pubmed]
PHST- 2021/05/20 06:01 [medline]
PHST- 2021/04/27 00:00 [pmc-release]
AID - 10.14740/jh818 [doi]
PST - ppublish
SO  - J Hematol. 2021 Apr;10(2):80-82. doi: 10.14740/jh818. Epub 2021 Apr 27.